Atomoxetine Dose Titration Schedule
For children and adolescents ≤70 kg: Start at 0.5 mg/kg/day, wait a minimum of 3 days, then increase to the target dose of 1.2 mg/kg/day; for those >70 kg and adults: start at 40 mg/day, wait a minimum of 3 days, then increase to 80 mg/day. 1
Weight-Based Dosing Algorithm
Children and Adolescents ≤70 kg
- Initial dose: 0.5 mg/kg/day (single morning dose or divided morning/late afternoon)
- Minimum waiting period: 3 days
- Target dose: 1.2 mg/kg/day
- Maximum dose: 1.4 mg/kg/day or 100 mg/day (whichever is less)
- Further titration: No additional benefit demonstrated above 1.2 mg/kg/day 1
Children and Adolescents >70 kg and Adults
- Initial dose: 40 mg/day (single morning dose or divided morning/late afternoon)
- Minimum waiting period: 3 days
- Target dose: 80 mg/day
- Further titration: After 2-4 additional weeks at 80 mg/day, may increase to maximum 100 mg/day only if optimal response not achieved and initial dose well-tolerated 1
Critical Timing Considerations
The minimum 3-day interval between initial and target dose is essential to minimize gastrointestinal adverse effects (nausea, vomiting, abdominal pain) and somnolence, which occur more frequently with rapid titration 2, 3. Research demonstrates that fast titration schedules significantly shorten time to onset of these adverse effects compared to slower approaches 4.
Slower titration with divided dosing (twice daily) during the first several weeks reduces the impact of treatment-emergent adverse events 5. Once-daily dosing shows significantly shorter time to onset for all common adverse effects in pediatric patients 4.
Special Population Adjustments
CYP2D6 Poor Metabolizers or Concurrent Strong CYP2D6 Inhibitors
When using strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine) or in known CYP2D6 poor metabolizers:
- Children/adolescents ≤70 kg: Start 0.5 mg/kg/day, increase to 1.2 mg/kg/day only after 4 weeks if symptoms fail to improve and initial dose well-tolerated
- Children/adolescents >70 kg and adults: Start 40 mg/day, increase to 80 mg/day only after 4 weeks if symptoms fail to improve and initial dose well-tolerated 1
This extended 4-week interval (versus the standard 3-day minimum) is necessary because approximately 7% of the population are poor metabolizers with significantly higher plasma levels and longer half-lives, increasing adverse effect risk 3.
Hepatic Impairment
- Moderate hepatic impairment (Child-Pugh Class B): Reduce initial and target doses to 50% of normal
- Severe hepatic impairment (Child-Pugh Class C): Reduce initial and target doses to 25% of normal 1
Common Pitfalls to Avoid
Do not increase dosage too rapidly. The 2019 AAP guideline specifically warns that "initial somnolence and gastrointestinal tract symptoms" occur "particularly if the dosage is increased too rapidly" 2. This is the most preventable cause of treatment discontinuation.
Do not assume higher doses are more effective. Evidence shows no additional benefit for doses above 1.2 mg/kg/day in children and adolescents 1, 6. The 1.8 mg/kg/day dose showed equivalent efficacy to 1.2 mg/kg/day but with potentially more adverse effects 6.
Monitor closely during dose changes. The FDA black box warning mandates close monitoring for suicidal ideation, clinical worsening, and unusual behavioral changes, especially during the first months of treatment and at times of dose change 3.
Maintenance Considerations
Allow adequate trial duration before declaring treatment failure. A trial period of at least 6-8 weeks, possibly longer, is recommended before evaluating overall tolerability and efficacy 5. Research in adolescents demonstrates that maintenance benefit is better sustained long-term with 1.4 mg/kg/day compared to 0.8 mg/kg/day 7.
Atomoxetine can be discontinued abruptly without tapering 1, unlike alpha-2 agonists (guanfacine, clonidine) which require gradual discontinuation to avoid rebound hypertension 2.